Effect of a Pseudoallergen-Free Diet in Chronic Spontaneous Urticaria: A Pilot Study

Esra SARAC1, Pelin KUTEYLA CAN2, Emek KOCATURK1

1 Department of Dermatology, Koc University School of Medicine, Istanbul, Turkey
2 Department of Dermatology, Bahcesehir University School of Medicine, Istanbul, Turkey

Corresponding Author: Emek Kocaturk ekocaturk@ku.edu.tr

ABSTRACT

Objective: The role of dietary factors in the etiopathogenesis of chronic spontaneous urticaria (CSU) has been a matter of discussion and it is widely accepted that most urticaria cases triggered by food are caused by pseudoallergic reactions. In this prospective study, our aim was to investigate the effect of a pseudoallergen-free diet (PAFD) on disease activity, the need for antihistamine use, and the quality of life in patients with CSU.

Materials and Methods: The study included adult patients who were on follow up for CSU for a duration of at least 6 months and had symptoms every day or every other day. The patients were given a food diary, which also included assessment of daily disease activity. The daily Urticaria Activity Score (UAS), the Chronic Urticaria Quality of Life Questionnaire score at baseline and at the 4th week, and frequency of antihistamine use were obtained. According to the change in UAS (ΔUAS), the patients' response to PAFD was classified as strong (ΔUAS≥8), partial (8>ΔUAS≥4), or no response (ΔUAS<4).

Results: Twenty-three patients, 19 females (82.6%) and 4 males (17.4%), completed the study, the mean age was 43±4.6 years. According to ΔUAS, 6 patients (26.1%) had strong response, 6 (26.1%) had partial response, and 11 (47.8%) were unresponsive to PAFD. The mean ΔUAS value of the patients who responded to PAFD was 8.1 (min:4, max:15). At the end of the study, 9 (39.1%) patients had a significant improvement in their quality of life. There were 6 (26%) patients who both responded to PAFD and had improved quality of life scores. The frequency of antihistamine use decreased in 10 (43.5%) patients.

Conclusion: PAFD may help decrease disease activity in CSU. We observed that the frequency of antihistamine use could be reduced and the patient's quality of life could be improved by adding PFAD to antihistamine therapy.

Keywords: Chronic spontaneous urticaria, diet, pseudoallergen-free diet, quality of life, treatment, urticaria

INTRODUCTION

Chronic spontaneous urticaria (CSU) is defined as urticaria and/or angioedema lasting longer than six weeks in the absence of identifiable physical or other inducible stimuli (1). Dietary factors have been suggested to have a role as a cause of CSU; however, IgE-mediated type I food allergy is considered rare (2). Although some patients blame food as a triggering factor for their attacks, most of these are considered to be caused by pseudoallergic reactions. It has been suggested that pseudoallergens trigger histamine release from cutaneous mast cells through a non-immunological mechanism, and intolerance to pseudoallergens might exacerbate CSU. Preservatives, antioxidants, sweeteners, colorants, salicylic acid, natural coloring and flavoring compounds are responsible for the reactions triggered by foods (3,4).

It has been reported that more than 30% of patients with CSU associate their attacks with food (5,6). Although patients cannot describe a single trigger specifically, a pseudoallergen-free diet (PAFD) trial for 3-4 weeks has been reported to provide some benefit, thus pointing to a possible role of pseudoallergens as triggering factors in CSU. Our hypothesis is that a regularly followed and scheduled PAFD may reduce the severity of the disease in particular CSU patients. The aim of this single-center prospective study was to investigate the effect of PAFD on
Pseudoallergen-Free Diet in Urticaria

MATERIALS and METHOD

The study included adult CSU patients with a disease duration of at least 6 months, who experienced urticaria symptoms every day or every other day, and who were poorly controlled with standard doses of second generation H1-antihistamines. Patients who had chronic inducible urticaria, and were pregnant, breastfeeding, under 18 years old, or receiving omalizumab or immunosuppressive treatment were excluded. The study was approved by the local Ethics Committee of Göztepe Training and Research Hospital (approval number: 2009/67-E) and written informed consent was obtained from all participants. Research and publication ethics were complied with. The patients were given a diary that included diet instructions and pseudoallergen-free recipes for every single day of the PAFD. They were asked to note each day in this diary the foods they consumed, the factors that triggered their urticaria attacks, and the use of additional drugs. The list of foods that the patients could consume or should refrain from during the study was added to the diary in a tabular form (Table I). In order to determine baseline disease activity, the patients refrained from any special diet on days 1-7, while PAFD was applied on days 8-31. The diary also included daily UAS [wheals and itching were scored from 0 to 3 (UAS daily)], frequency of daily antihistamine use, and the use of additional drugs. The list of foods that the patients could consume or should refrain from during the study was added to the diary in a tabular form (Table I). In order to determine baseline disease activity, the patients refrained from any special diet on days 1-7, while PAFD was applied on days 8-31. The diary also included daily UAS [wheals and itching were scored from 0 to 3 (UAS daily)], frequency of daily antihistamine use, and the Chronic Urticaria Quality of Life (CU²-QoL) questionnaire score on days 7 (baseline) and 31.

The change in UAS (ΔUAS) was calculated by subtracting total UAS over the last 4 days (final UAS4) from the total UAS on days 4-7 (basal UAS4). Accordingly, the patients’ response to PAFD was classified as strong (ΔUAS ≥ 8), partial (8 > ΔUAS ≥ 4), and no response (ΔUAS < 4). A change of ≥ 8 points in CU²-QoL scores between day 7 and 31 was considered as significant change (7). The patients were asked not to use antihistamines as much as possible during the study period and also during one week before the PAFD period; and note in the diary if they used these. Antihistamines were allowed only when extreme itching could not be tolerated and there was generalized urticaria or angioedema. The changes in antihistamine use were calculated based on the difference between the total number of antihistamines taken on days 27-31 and the total number of antihistamines taken on days 3-7.

Statistical Analysis

Statistical analyses were performed using the SPSS software version 26.0 (Statistical Package for Social Sciences, SPSS Inc., Chicago, IL, USA). All numerical variables were reported as the mean ± standard deviation, median, frequency and percentages. P values lower than 0.05 were considered significant. For samples that were not normally distributed, the Mann-Whitney U test and Kruskal-Wallis test were used for comparing the scores of the groups.

RESULTS

Twenty-three patients completed the study. Of these patients, 19 (82.6%) were female and 4 (17.4%) were male, with a mean age of 43 ± 4.6 years (range:18-67). Baseline characteristics of the patients are shown in Table II. According to ΔUAS, 6 patients (26.1%) had a strong response, 6 (26.1%) had a partial response, and 11 (47.8%) were unresponsive (Figure 1). The mean ΔUAS value of the patients who responded to PAFD was 8.1±3.6 (range;4-15, median;7.5). At the end of the study, 9 (39.1%) patients had a significant improvement in their quality of life (39.1%). There were 6 (26%) patients who responded to PAFD both with a decrease in UAS scores and also with improved quality of life scores. The frequency of antihistamine use decreased in 10 (43.5%) patients; the mean value of AH decrease was 3±2.6 [median; 2 (range; 1-9)] in these patients. Although the difference between the groups was not statistically significant, antihistamine use was slightly higher in strong-responders (p=0.181).

The mean number of change in antihistamine use was 1.31.2 in strong responders, 0.60.4 in partial responders, and -0.51.2 in non-responders. Distribution of the patients at week 4 according to evaluation parameters and AH need is shown in Figure 2.
DISCUSSION

The role of nutrients, which are the main sources of life, in the etiology of chronic urticaria (CU) has been questioned for a long time, as in many other diseases. Although foods can trigger allergic reactions, actual allergy rates are much lower than patient estimates. As a result of the development of the food industry and the widespread use of food additives, the frequency of pseudoallergic reactions triggered by food is increasing. Studies have reported that the rate of sensitivity to food and nutritional additives is 1-68% (8). It has been suggested that additives such as stabilizers, preservatives, colorants, flavorants and sweeteners, as well as naturally occurring aromas and substances such as histamine and salicylic acid in foods are responsible for pseudoallergic reactions (4).
enzyme activity or recommendation of a histamine-poor diet may also be useful to control the disease.

It is known that salicylic acid derivatives cause the disruption of the balance between prostaglandin and leukotriene pathways by inhibiting cyclooxygenase 1 (18). It can be considered that salicylates in foods may cause attacks in patients with CSU through a similar mechanism. In a recently published prospective study, it was shown that a low salicylate diet significantly reduced the symptoms of asthma, rhinosinusitis, and urticaria in patients with hypersensitivity to aspirin or non-steroidal anti-inflammatory drugs (19). In another study investigating the activation of the leukotriene pathway after pseudoallergen intake, it was reported that the urinary leukotriene levels of patients with chronic urticaria responding to PAFD were significantly lower than those who did not respond to this diet, and there was a significant correlation between reduced urticaria activity and reduced urinary leukotriene levels (20).

In CSU, which significantly reduces the quality of life, a significant proportion of patients suspect that there is a relationship between urticaria attacks and food intake and expect a dietary recommendation that lists which foods to avoid for the control of their disease. The clinical findings of urticaria triggered by pseudoallergens are similar to those of type I allergic reactions, and the absence of a specific laboratory or skin test makes the diagnosis difficult. Elimination diets and oral provocation tests should be applied for a definitive diagnosis. Unlike type I allergies, symptoms appear more than four hours after pseudoallergen ingestion and disappear after 10-14 days of following the recommended diet (3,21). The European Academy of Allergy and Clinical Immunology, Global Allergy and Asthma European Network, European

The pathophysiology of pseudoallergen-induced urticaria has not yet been fully elucidated. It is known that small molecules of pseudoallergens cannot bind directly to IgE and do not act like haptens (9). No prior exposure is required for the pseudoallergic reactions to develop. In addition, it is thought that other triggering factors such as the impaired permeability of the gastroduodenal mucosa and the presence of anti-FcepsilonRI-alpha autoantibodies may have a synergistic effect (10-13).

Histamine, which emerges in the gastrointestinal tract after the digestion of food, is broken down mainly by the enzyme diamine oxidase (DAO). It has been shown that an increased blood histamine level can trigger urticaria in individuals with DAO activity deficiency, and enzyme supplementation or a histamine-deficient diet can reduce urticaria attacks (14-17). If patients with CSU also describe gastrointestinal system complaints such as bloating, pain, and diarrhea after food intake, the monitoring of DAO

Table II: Baseline characteristics of the patients

<table>
<thead>
<tr>
<th></th>
<th>Mean (sd)</th>
<th>Min - Max</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>43 ± 4.6</td>
<td>18 - 67</td>
<td></td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td>19 (82.6)</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td>4 (17.4)</td>
</tr>
<tr>
<td><strong>Basal UAS4</strong></td>
<td>11.8 ± 6.9</td>
<td>0 - 24</td>
<td></td>
</tr>
<tr>
<td>(sum of the scores on days 4-7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Basal AH need</strong></td>
<td>3.1 ± 2.1</td>
<td>0 - 20</td>
<td></td>
</tr>
<tr>
<td>(number of tablets taken on days 3-7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Basal CU2-QoL (day 7)</strong></td>
<td>1.8 ± 12.4</td>
<td>29 - 88</td>
<td></td>
</tr>
</tbody>
</table>

Figure 2. Distribution of the patients at week 4 according to the urticaria activity score (UAS), quality of life scores (QoL), and AH need.

Histamine, which emerges in the gastrointestinal tract after the digestion of food, is broken down mainly by the enzyme diamine oxidase (DAO). It has been shown that an increased blood histamine level can trigger urticaria in individuals with DAO activity deficiency, and enzyme supplementation or a histamine-deficient diet can reduce urticaria attacks (14-17). If patients with CSU also describe gastrointestinal system complaints such as bloating, pain, and diarrhea after food intake, the monitoring of DAO
there were 6 (26%) patients that both responded to PAFD by means of improvement in disease activity as well as improved quality of life scores. However, 1 (4.3%) patient with a strong response and 1 (4.3%) with a partial response to PAFD reported a decrease in quality of life according to the questionnaires. This suggests that dietary restrictions or prohibited food intake may also adversely affect the quality of life of some patients.

Magerl et al. have used the changes in urticaria severity and DLQI to classify chronic urticaria. They defined cases in which the quality of life deteriorated despite the decrease in disease activity as ‘addictive subjects’ and suggested that these patients would prefer to eat their daily food freely despite urticaria exacerbations. The authors reported that 7% of the patients belonged to this group (4), which is similar to our findings. In a study by Bunselmeyer et al., it was reported that the quality of life significantly improved in all patients who responded to PAFD (25).

It is known that CU affects performance in school and work life and reduces the quality of life similar to or more than moderate-severe psoriasis, atopic dermatitis, asthma, and coronary artery disease (26-29). In the current study, we used the Turkish version of the CU2-QoL questionnaire, which was developed to evaluate the physical, psychosocial and daily effects of chronic urticaria for the last two weeks and previously shown to be reliable and valid (30,31). Patients who have a positive response to the dietary changes are also expected to have increased quality of life in line with reduced urticaria activity. At the end of our study, a significant improvement was observed in the quality of life of in almost 40% of the patients, and there were 6 (26%) patients that both responded to PAFD by means of improvement in disease activity as well as improved quality of life scores. However, 1 (4.3%) patient with a strong response and 1 (4.3%) with a partial response to PAFD reported a decrease in quality of life according to the questionnaires. This suggests that dietary restrictions or prohibited food intake may also adversely affect the quality of life of some patients.

Magerl et al. have used the changes in urticaria severity and DLQI to classify chronic urticaria. They defined cases in which the quality of life deteriorated despite the decrease in disease activity as ‘addictive subjects’ and suggested that these patients would prefer to eat their daily food freely despite urticaria exacerbations. The authors reported that 7% of the patients belonged to this group (4), which is similar to our findings. In a study by Bunselmeyer et al., it was reported that the quality of life significantly improved in all patients who responded to PAFD (25).

Antihistamines are the first-line treatment for disease management in CSU. Disease activity can be calculated based on daily symptoms, clinical signs, and the need for antihistamine use (standard doses or up to four-fold dose). In the current study, antihistamine use decreased in 43.5% of the patients who adopted the PAFD. King et al. reported that the need for antihistamine use decreased in patients with chronic urticaria who were prescribed a low histamine diet for 6 weeks (32).

Table III: Summary of the studies with response to a pseudoallergen-free diet

<table>
<thead>
<tr>
<th>Authors (reference number)</th>
<th>Number of patients</th>
<th>Duration of the diet</th>
<th>Diet response rate</th>
<th>Provocation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magerl et al. (4)</td>
<td>140</td>
<td>Three weeks</td>
<td>34%</td>
<td>Not performed</td>
</tr>
<tr>
<td>Rajan et al. (8)</td>
<td>100</td>
<td>Not applicable</td>
<td>Elimination diet was not performed</td>
<td>Two patients had a positive reaction in the provocation test with 11 food additives.</td>
</tr>
<tr>
<td>Akoglu et al. (20)</td>
<td>34</td>
<td>Four weeks</td>
<td>41%</td>
<td>Additive</td>
</tr>
<tr>
<td>Zuberbier et al. (22)</td>
<td>64</td>
<td>Two weeks</td>
<td>73%</td>
<td>Thirty-seven percent of diet responders had positive results in the placebo-controlled tests of food additives.</td>
</tr>
<tr>
<td>Pigatto et al. (23)</td>
<td>202</td>
<td>Not applicable</td>
<td>62%</td>
<td>Challenge test with 6 additives was found to be positive in 31.4% of 264 patients whose urticaria improved after food additive free diet.</td>
</tr>
<tr>
<td>Di Lorenzo et al. (24)</td>
<td>838</td>
<td>Four weeks</td>
<td>31.5%</td>
<td>Eighty-six percent of full responders and all partial responders showed symptoms with incremental build-up food challenge.</td>
</tr>
<tr>
<td>Bunselmayer et al. (25)</td>
<td>153</td>
<td>Five weeks</td>
<td>68%</td>
<td>Not performed</td>
</tr>
<tr>
<td>Current study</td>
<td>23</td>
<td>31 days</td>
<td>52%</td>
<td>Not performed</td>
</tr>
</tbody>
</table>

Dermatology Forum, and World Allergy Organization urticaria guideline recommend PAFD for three weeks as an alternative treatment option in patients with CSU that do not respond to conventional treatments (1).
The main limitations of this study include the limited number of patients, lack of a provocation test with pseudoallergen-rich foods after PAFD, lack of a control group, and absence of any restriction on the use of other drugs such as NSAIDs and aspirin. Also, antihistamine use was not fully restricted during the study. This may cause an overestimation of the dietary response by reducing the severity of the disease. Due to the limited number of patients and lack of clinical or laboratory parameters of the patients, it was not possible to determine markers that define response to PAFD treatment.

**CONCLUSION**

In conclusion, although the role of diet in the pathogenesis and treatment of urticaria is not yet fully understood, the results of our study suggest that PAFD may be beneficial in a selected group of patients with CSU who do not have an adequate response to standard treatments. We recommend to use this diet not as a fundamental treatment but as supplementary to ongoing pharmacological treatment in CSU patients. With PAFD, an amelioration in the severity of the disease and a decrease in the use of antihistamines as well as an increase in the quality of life can be achieved in a certain group of patients.

**Conflict of Interest**

ES and PKC have no conflicts of interest. EK has received honoraria (advisory board, speaker) from Novartis, Sanofi, Menarini, LaRoche Posey and Bayer.

**Authorship Contributions**


**REFERENCES**


